US5135919A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and a pharmaceutical composition for the inhibition of angiogenesis
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1988-03-25
•
Granted: 1992-08-04
•
Expires: 2008-03-25
Abstract
Abstract Fumagillin and its salts have an angiogenesis inhibiting activity and are useful for prophylaxis and treatment of diseases induced by abnormally stimulated neovascularization. The invention also provides certain pharmaceutical compositions comprising fumagillin or its salt, and an agent which potentiates angiogenesis inhibition such as heparin and sulfated cyclodextrins such as beta-cyclodextrin tetradecasulfate.
Inventors
- 👤 Judah Folkman
- 👤 Takeshi Fujita
- 👤 Donald Ingber
- 👤 Tsuneo Kanamaru
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 23:20
CPC Classifications
B; B82; B82Y; B82Y5/00; A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/56; A61K31/57; A61K47/00; A61K47/50; A61K47/69; A61K47/6949; A61K47/6951; A61L; A61L27/00; A61L27/50; A61L27/54; A61P; A61P9/00; C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/50; C07K14/503; C08; C08B; C08B37/00; C08B37/0006; C08B37/0009; C08B37/0012; A61K38/00; A61L2300/00; A61L2300/20; A61L2300/23; A61L2300/236; A61L2300/40; A61L2300/416; A61L2300/80; A61L2300/802
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
29 words
A method of inhibiting angiogenesis in a mammal, comprising administering an amount of fumagillin effective for the inhibition of angiogenesis or a pharmaceutically acceptable salt thereof to the mammal.
Claim 2
Independent Claim
29 words
A method of inhibiting angiogenesis in a mammal, comprising administering an amount of fumagillin effective for the inhibition of angiogenesis or a pharmaceutically acceptable salt thereof to the mammal.
Claim 3
Independent Claim
29 words
A method of preventing angiogenesis in a mammal, comprising administering an amount of fumagillin effective for the prevention of angiogenesis or a pharmaceutically acceptable salt thereof to the mammal.
Claim 4
Independent Claim
29 words
A method of preventing angiogenesis in a mammal, comprising administering an amount of fumagillin effective for the prevention of angiogenesis or a pharmaceutically acceptable salt thereof to the mammal.
Claim 5
Dependent Claim
17 words
The method according to claim 1 or 2, wherein the angiogenesis is caused by abnormally stimulated neovascularization.
Claim 6
Dependent Claim
14 words
The method according to claim 3, wherein the abnormally stimulated neovascularization is diabetic retinopathy.
Claim 7
Dependent Claim
13 words
The method according to claim 3, wherein the abnormally stimulated neovascularization is trachoma.
Claim 8
Dependent Claim
23 words
The method according to claim 1 or 2, wherein fumagillin is administered orally in amount of 0.1 mg/kg to 200 mg/kg per day.
Claim 9
Dependent Claim
25 words
The method according to claim 1 or 2, wherein the fumagillin is administered intravenously in an amount of 0.1 mg/kg to 20 mg/kg per day.
Claim 10
Dependent Claim
31 words
The method according to claim 1 or 2, wherein an aqueous solution of fumagillin sodium salt at a concentration from 0.001% to 3% (w/v) is administered in the form of eye-drops.
Claim 11
Dependent Claim
48 words
The method of claim 1 or 2, further comprising administering in conjunction with fumagillin or a salt thereof, an effective amount of a potentiator of said fumagillin selected from heparin and a sulfated cyclodextrin, the ratio of potentiator to fumagillin by weight being between about 1:10 to 30:1.
Claim 12
Dependent Claim
13 words
The method of claim 9, wherein the sulfated cyclodextrin is beta cyclodextrin tetradecasulfate.
Claim 13
Dependent Claim
45 words
A pharmaceutical composition for the treatment of angiogenesis in mammals comprising fumagillin or a pharmaceutically acceptable salt thereof and a potentiator of said fumagillin selected from heparin and a sulfated cyclodextrin, the ratio o potentiator to fumagillin by weight being between about 1:10 to 30:1.
Claim 14
Dependent Claim
45 words
A pharmaceutical composition for the treatment of angiogenesis in mammals comprising fumagillin or a pharmaceutically acceptable salt thereof and a potentiator of said fumagillin selected from heparin and a sulfated cyclodextrin, the ratio o potentiator to fumagillin by weight being between about 1:10 to 30:1.
Claim 15
Dependent Claim
14 words
The pharmaceutical composition of claim 11, wherein the sulfated cyclodextrin is beta cyclodextrin tetradecasulfate.
Claim 16
Dependent Claim
14 words
The pharmaceutical composition of claim 11 or 12, further comprising a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-08-04 | 1996-02-03 | 1996-08-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-08-04 | 2000-02-03 | 2000-08-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-08-04 | 2004-02-03 | 2004-08-04 | $7700.00 | Window Closed / Lapsed |